Exploring the Role of Alcohol Metabolizing Genotypes in a 12-Week Clinical Trial of Naltrexone for Alcohol Use Disorder

Exploring the Role of Alcohol Metabolizing Genotypes in a 12-Week Clinical Trial of Naltrexone for Alcohol Use Disorder

<b>Background:</b> The efficacy of naltrexone in the treatment of alcohol use disorder (AUD) has been associated with a set of variables not directly related with the expression of opioid receptors. All the variables have been found to be highly associated with AUD itself or more severe...

Full description

Bibliographic Details
Main Authors: João M. Castaldelli-Maia, André Malbergier, Adriana B. P. de Oliveira, Ricardo A. Amaral, André B. Negrão, Priscila D. Gonçalves, Antonio Ventriglio, Domenico de Berardis, Juliana de Antonio, Isabela Firigato, Gilka J. F. Gattás, Fernanda de Toledo Gonçalves
Format: Article
Language:English
Published: MDPI AG 2021-10-01
Series:Biomolecules
Subjects:
alcohol
naltrexone
genotyping
<i>ADH1B</i>
<i>ADH1C</i>
<i>ALDH2</i>
Online Access:https://www.mdpi.com/2218-273X/11/10/1495

Internet

https://www.mdpi.com/2218-273X/11/10/1495

Similar Items